Biopharmas in Asia-Pacific raising money in public or private financings, including: Bone Therapeutics, Connect Biopharmaceuticals, Opthea, Rnaimmune, Sirnaomics.
Privately held Alzheon Inc. picked up a $47 million grant from the NIH’s National Institute on Aging that will last over five years to support a phase III clinical trial of its oral brain-penetrant small molecule ALZ-801 to treat Alzheimer’s disease.
Practice growth platform Patientpop scooped up $50 million in a series C financing led by HLM Venture Partners. The new funds are earmarked for telehealth and virtual care solutions to help private practices adapt to a rapidly health care environment and the challenges of seeing and treating patients during a global pandemic.
PARIS – Curadigm SAS has raised $1 million in non-dilutive funding from Bpifrance (Banque publique d’investissement in France), for development of its Nanoprimer technology. Bpifrance’s Deep Tech program in France recognizes health tech companies with breakthrough innovation and strong commercial potential.
Informed Data Systems Inc. (IDS), doing business as One Drop, scooped up $98.7 million in new financing and commitments to accelerate the expansion of its digital health platform beyond diabetes. The company raised $34.7 million in a series C round led by Bayer AG, of Leverkusen, Germany. Bayer also committed $64 million in development fees and commercial milestones related to a 2019 licensing agreement to leverage the One Drop solution across multiple therapeutic areas.
LONDON – Biofidelity Ltd. has raised US$12 million in a series A, enabling it to start commercialization of a novel, low-cost, chemistry-based diagnostic for detecting all actionable lung cancer mutations. The Cambridge, U.K.-based company claims the test can detect a single molecule of mutated DNA against the background of billions of healthy molecules in a patient sample, without the need for DNA sequencing.
RSS
